Evidence map›Paper›PMID 39313691›Full record

SynthesisHerz2025

Efficacy of sacubitril-valsartan vs. angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in preventing atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.

Fernando Baía Bezerra, Luis Eduardo Rodrigues Sobreira, Vitor Kendi Tsuchiya Sano, Artur de Oliveira Macena Lôbo, Jorge Henrique Cavalcanti Orestes Cardoso, Francinny Alves Kelly, Francisco Cezar Aquino de Moraes, Fernanda Marciano Consolim-Colombo

Erratum issuedAbstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in Herz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Fernando Baía BezerraAnhembi Morumbi University, Avenida Deputado Benedito Matarazzo, 6070 - Jardim Aquarius, São José Dos Campos, Brazil. fernandobaiabezerra@gmail.com.ORCID http://orcid.org/0009-0007-2587-4176
Luis Eduardo Rodrigues SobreiraFederal University of Pará, 68371-040, Altamira, Brazil.ORCID http://orcid.org/0009-0003-3006-5489
Vitor Kendi Tsuchiya SanoFederal University of Acre, 69920-900, Rio Branco, Brazil.ORCID http://orcid.org/0000-0001-8317-1857
Artur de Oliveira Macena LôboFederal University of Pernambuco, 50670-901, Recife, Brazil.ORCID http://orcid.org/0009-0003-0637-0387
Jorge Henrique Cavalcanti Orestes CardosoUniversity of Pernambuco, 50100-130, Recife, Pernambuco, Brazil.ORCID http://orcid.org/0000-0003-0316-8047
Francinny Alves KellyDante Pazzanese Cardiology Institute, 04012-909, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-0706-6929
Francisco Cezar Aquino de MoraesFederal University of Para, 66075-110, Belem, Brazil.ORCID http://orcid.org/0000-0003-0623-8135
Fernanda Marciano Consolim-ColomboHeart Institute, 05403-900, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-3220-019X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients who have undergone catheter ablation for atrial fibrillation (AF) may experience recurrence of this condition. The efficacy of sacubitril-valsartan (S/V) in preventing AF recurrence compared with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) is not established. This meta-analysis aimed to establish the best therapeutic choice for preventing AF recurrence after catheter ablation.

methodA systematic search of the PubMed, Embase, and Cochrane databases was conducted for randomized controlled trials (RCTs) and observational studies comparing the use of S/V with ACEI/ARB in patients who underwent catheter ablation. Results are presented as mean difference (MD) with 95% confidence interval (CI). Heterogeneity was assessed with the I

resultsThree RCTs and one cohort study, comprising 642 patients with 319 patients in the S/V group and 323 in the control group, were included. Follow-up ranged from 6 to 36 months, with mean ages ranging from 58.9 to 65.8 years. A significant reduction in persistent AF occurrence was demonstrated favoring the S/V group (RR: 0.54; 95% CI: [0.41, 0.70]; p = 0.000004; I

conclusionThis meta-analysis demonstrated the efficacy of S/V in reducing the incidence of AF in patients undergoing catheter ablation compared with the use of ACEI/ARB. However, more RCTs are needed for a comprehensive evaluation of its efficacy in reducing AF recurrence after catheter ablation in clinical practice.

Indexed as

AminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAtrial FibrillationCatheter AblationTetrazolesAgedBiphenyl CompoundsDrug CombinationsEvidence-Based MedicineFemaleHumansMaleMiddle AgedPrevalenceSecondary PreventionAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanAblationAngiotensin II receptor blockersAtrial fibrillationRecurrenceSacubitril–valsartan

Identifiers

PMID39313691

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.